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Summary
Current knowledge of the haematological and onco-haemato-
logical complications of type 1 Gaucher disease has been
reviewed with the aim of identifying best clinical practice for
treatment and disease management. It was concluded that: (i)
Awareness of typical patterns of cytopenia can help clinicians
distinguish haematological co-morbidities. (ii) Red blood cell
studies andcomplete iron metabolismevaluation atbaseline are
recommended. (iii) Haemoglobin levels deﬁning anaemia
should be raised and used in Gaucher disease treatment and
monitoring.(iv)Surgeonsshouldbeawareofpotentialbleeding
complications during surgery in Gaucher patients. The higher
incidence of multiple myeloma in Gaucher disease suggests that
Gaucher patients should have their immunoglobulin proﬁle
determined at diagnosis and monitored every 2 years (patients
<50 years) or every year (patients >50 years). If monoclonal
gammopathy of undetermined signiﬁcance (MGUS) is found,
general MGUS guidelines should be followed. Future studies
should focus on the utility of early treatment to prevent
immunoglobulin abnormalities and multiple myeloma.
Keywords: Gaucher disease, clinical haematology, haemato-
logical malignancy.
Non-neuronopathic (type 1) disease is the most common form
of Gaucher disease, a rare condition characterized by an
autosomal recessive inherited deﬁciency in the lysosomal
enzyme beta-glucocerebrosidase (E 3.2.1.45). Common disease
manifestations include hepatosplenomegaly, thrombocyto-
penia and bleeding, anaemia and skeletal disease (Cox &
Schoﬁeld, 1997). Untreated, symptomatic patients may suffer
serious morbidity and mortality from haematological and
skeletal complications, liver failure, severe pulmonary disease
and infection (Lee, 1982). Patients endure reduced quality of
life (Giraldo et al, 2005) and reduced lifespan compared with
healthy controls (vom Dahl et al, 2006a).
Early clinically signiﬁcant symptoms often reﬂect the haem-
atological manifestations of disease such as, unexplained fatigue
due to anaemia, frequent gum or nosebleeds as a result of
thrombocytopenia, coagulopathy and platelet dysfunction, and
abdominal distension and pain from splenomegaly. Conse-
quently, haematologists are often involved in the initial diagno-
sis, assessment and on-going medical care of Gaucher patients.
The course of type 1 Gaucher disease is highly variable.
There are marked differences between individuals in the age of
onset of clinical symptoms, clinical expression, rates of disease
progression and life expectancy (Maaswinkel-Mooij et al,
2000). Clinical phenotype cannot be accurately predicted from
genotype (Mistry & Germain, 2006) although early onset is
generally associated with more rapidly progressive and severe
disease (Zimran et al, 1992). Gaucher disease may be associ-
ated with a variety of co-morbidities (Perez-Calvo et al, 2000)
including malignant disease, particularly multiple myeloma
(de Fost et al, 2006).
Enzyme replacement therapy (imiglucerase [Cerezyme ];
Genzyme Corporation, Cambridge, MA, USA) reverses or
ameliorates many of the systemic manifestations of Gaucher
disease (Weinreb et al, 2002), prevents disease progression and
complications (European Agency for the Evaluation of Medi-
cinal Products (EMEA), 2005), and is considered the gold
standard treatment for Gaucher type 1 and type 3 patients (Cox
et al, 2003). Substrate reduction therapy (miglustat, [Zaves-
ca ]; Actelion Pharmaceuticals, Allschwill, Switzerland) has
alsobeenlicensed fortype1Gaucher diseaseandmaybeused in
adult patients with mild to moderate disease for whom enzyme
replacement therapy is not a therapeutic option (EMEA, 2006).
The heterogeneity of type 1 Gaucher disease demands an
individualized approach to treatment and disease management
to ensure optimal outcomes (Weinreb et al, 2002). Compre-
hensive therapeutic goals and monitoring guidelines were
agreed in 2004 (Pastores et al, 2004; Weinreb et al, 2004). They
form the basis for an evidence-based disease management
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preventing or reducing the risk of long-term disease
complications (Andersson et al, 2005). This study reviews the
current knowledge of the haematological aspects of Gaucher
disease with the purpose of identifying best clinical practice in
the treatment and monitoring of haematological and onco-
haematological complications in Gaucher patients.
Aims and methods
On the 18 October 2006, a group of European haematologists
and European experts in Gaucher disease convened to:
1 Review current knowledge on the haematological aspects
and complications of Gaucher disease with the help of
relevant data from non-Gaucher haematology.
2 Identify haematological aspects that can lead to increased
awareness and earlier suspicion/differential diagnosis of
Gaucher disease by general haematologists.
3 Determine which Gaucher aspects/complications warrant
initial assessment and ongoing monitoring in known
Gaucher patients.
4 Review current Gaucher treatment goals (Pastores et al,
2004) and assessment/monitoring guidelines (Weinreb
et al, 2004) for haematological aspects/complications of
Gaucher disease.
5 Provide advice to both haematologists and non-haematol-
ogists for optimal treatment and monitoring of Gaucher
patients.
Participants were asked to review and present evidence from
peer-reviewed literature, the International Collaborative Gau-
cher Group (ICGG) database (Charrow et al, 2000) and from
their own clinical experience to support their recommenda-
tions. Because of the rarity of Gaucher disease and the
consequent lack of randomized trial data, recommendations
are based on evidence from observational studies, case reports
and expert opinion. Recommendations are graded according
to Smith et al (2006).
Results
Non-malignant haematological disease
Cytopenia is an almost universal ﬁnding in untreated Gaucher
patients. Anaemia, thrombocytopenia and to a lesser extent,
leucopenia, may be observed simultaneously or independently
(Zimran et al, 2005a). Before the availability of enzyme
replacement therapy, splenectomy was frequently carried out
to reduce severe cytopenia due to functional hypersplenism
and to reduce the mechanical effects of an enlarged spleen on
abdominal viscera (Salky et al, 1979).
Anaemia. Data from the ICGG Registry shows that 36% of
enroled patients were anaemic at diagnosis, as deﬁned by the
haemoglobin levels shown in Table I. Beutler and Waalen
(2006) pointed out that the criteria for deﬁning anaemia were
widely based on World Health Organization expert committee
recommendations made over 40 years ago, and which do not
reﬂect differences between ethnic groups. They propose new
haemoglobin lower limits deﬁning anaemia for black and
white adults (Beutler & Waalen, 2006) (Table II). These are
relevant in Gaucher disease where higher incidence is
associated with certain ethnicities (Cox & Schoﬁeld, 1997)
and where it could be useful to relate the degree of anaemia
to ethnicity. Most cases of anaemia in Gaucher patients are
thought to be related to increased red blood cell destruction
in the spleen (Zimran et al, 2005a). Pre-treatment, severe and
moderate anaemia has been shown to be more prevalent in
non-splenectomized compared with splenectomized patients
(Weinreb et al, 2002). Nevertheless, it has been shown that
there is no direct correlation between the degree of
splenomegaly and degree of cytopenias (Gielchinsky et al,
1999), suggesting that other mechanisms may be involved.
These may include Gaucher cell inﬁltration into bone marrow
(Poll et al, 2002) with consequent pancytopenia, and other
causes (alone or in combination), such as iron deﬁciency
(which in addition to the common causes of diet,
menstruation and pregnancy, can also occur as a
consequence of blood loss in Gaucher patients with
a bleeding tendency), alterations in iron metabolism and
Table I. Current deﬁnitions of anaemia used in Gaucher disease
therapeutic goals and monitoring guidelines (Pastores et al, 2004;
Weinreb et al, 2004).
Children Haemoglobin (g/l)
Younger than 6 months <101
6 months – 2 years <95
2 years – 12 years <105
Males older than 12 years <120
Females older than 12 years <110
Table II. Proposed lower limits of normal for haemoglobin concen-
tration of the blood for white and black adults (Beutler & Waalen,
2006).
Group Haemoglobin (g/l)
White men (age)
20–59 137
60+ 132
White women
20–59 122
60+ 122
Black men
20–59 129
60+ 127
Black women
20–59 115
60+ 115
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and autoimmune haemolytic anaemia (Haratz et al, 1990).
Autoimmune haemolytic anaemia is sometimes associated
with recurrent abortions in women with Gaucher disease
(Sherer et al, 2002). Anaemia may also result from co-
morbidities such as myelodysplastic syndrome and
haematological malignancy (Zimran et al, 2005a).
In Gaucher disease, ferritin levels are generally elevated
without other biochemical evidence of iron overload (Morgan
et al, 1983) consistent with anaemia of chronic disease (Nairz
& Weiss, 2006), whereas typical iron deﬁciency anaemia is
characterized by low serum iron, low transferrin saturation
and low ferritin levels. In chronic inﬂammation, normal iron
homeostasis is disrupted by the release of pro- and anti-
inﬂammatory cytokines (Ludwiczek et al, 2003) with possible
dysregulation of hepcidin, a key liver-derived iron regulator
(Fleming & Sly, 2001). Certain proinﬂammatory cytokines that
are likely to increase hepcidin, such as interleukin (IL) 6
(Wrighting & Andrews, 2006), may be increased in the serum
of patients with Gaucher disease (Allen et al, 1997) but effects
on hepcidin levels have not been evaluated.
As well as reduced red cell quantity there is also evidence of
decreased red cell quality in Gaucher disease. While this might
be expected in patients without a functioning spleen, increased
cell aggregation has been demonstrated in both asplenic and
spleen-intact Gaucher patients (Bax et al, 2005). No correla-
tion between red cell aggregation index and disease severity,
plasma ﬁbrinogen concentration, genotype or history of
enzyme therapy has been found (Adar et al, 2006).
Thrombocytopenia. Of patients enroled in the ICGG Gaucher
Registry, 15% demonstrated severe thrombocytopenia with
platelet counts less than 60 · 10
9/l, 45% demonstrated
moderate thrombocytopenia (platelets >60–<120 · 10
9/l)
and 40% demonstrated mild thrombocytopenia (platelets
>120–<150 · 10
9/l) at diagnosis (ICGC Registry 2005
Annual Report, unpublished observations). As with anaemia,
thrombocytopenia is related to hypersplenism and/or
inﬁltration of bone marrow with Gaucher cells but, again,
there is no direct correlation with splenomegaly (Weinreb
et al, 2002). Complicating factors, such as immune
thrombocytopenia, may result in persistently low-platelet
counts (Haratz et al, 1990).
Bleeding tendency may not always be related to absolute
platelet counts but may be inﬂuenced by coagulation factor
deﬁciencies or abnormal platelet function. Acquired coagula-
tion factor deﬁciencies have been demonstrated in Gaucher
disease (Hollak et al, 1997a; Deghady et al, 2006). The
mechanism involved is unclear but may include low-grade
disseminated intravascular coagulation or sequestration of
coagulation factors by substrate loaded cells. Speciﬁc inherited
coagulation factor deﬁciencies exist among certain ethnic
groups, for example, factor XI deﬁciency amongst Ashkenazi
Jews (Seligsohn & Modan, 1981), a group that also demon-
strates increased incidence of Gaucher disease (Cox & Scho-
ﬁeld, 1997). Some patients with relatively high platelet counts
and normal coagulation tests have haemorrhagic episodes that
may be associated with abnormal platelet aggregation (Gillis
et al, 1999).
Leucopenia. Leucopenia, which may result from bone marrow
inﬁltration by Gaucher cells and/or hypersplenism, rarely
requires intervention in Gaucher patients. Both asplenic and
spleen-intact Gaucher patients can suffer repeated pyogenic
infections thought to related to deﬁcient neutrophil function
rather than decreased neutrophil counts (Zimran et al, 1994)
and/or compromised monocyte phagocytic and respiratory
burst capacity caused by glucocerebroside accumulation
(Marodi et al, 1995). Splenectomized patients (from any
cause) have an increased and ongoing risk of sepsis
(Kotsanas et al, 2006). Increased white blood cell counts may
also occur in Gaucher patients after splenectomy and may
signal other pathologies, such as the development of
lymphoproliferative disorders.
Therapeutic goals for cytopenia. Therapeutic goals for
imiglucerase suggest that haemoglobin levels should be
restored to normal or near normal levels within 12–
24 months of starting treatment (in the absence of iron
deﬁciency or any other co-morbidity associated with anaemia).
Associated aims are to reduce the need for blood transfusions
and to ameliorate anaemia-related symptoms such as fatigue
and, in older patients, dyspnoea and angina (Pastores et al,
2004).
Thrombocytopenia, independent of other symptoms, is
deﬁned by platelet counts of <150 · 10
9/l. Thrombocytopenia
sufﬁcient to justify initiation of imiglucerase therapy is deﬁned
by repeated platelet counts of <100 · 10
9/l. Therapeutic goals
aim to prevent spontaneous bleeding, whether caused by low
platelet numbers, platelet defects or coagulation abnormalities.
Normal platelet counts should be achieved in splenectomized
patients within 1 year, and low to normal platelet counts in
patients with moderate thrombocytopenia within 2 years.
For patients with severe thrombocytopenia, the goal is to
sustain increases in platelet counts although complete nor-
malization may be impossible (Pastores et al, 2004). Some
patients have a highly compromised platelet response because
of initial massive splenomegaly (Weinreb et al, 2002) and or
severe bone marrow inﬁltration (Grabowski et al, 1998). The
avoidance of splenectomy is an important treatment goal in
Gaucher disease (Pastores et al, 2004) as splenectomy increases
susceptibility to infection (Kotsanas et al, 2006), may exacer-
bate bone disease (Schiffmann et al, 2002), hepatic complica-
tions (Lachmann et al, 2000) and/or pulmonary disease
(Mistry et al, 2002).
Deﬁciencies in coagulation factors have been partially
corrected following 12 months of enzyme treatment (Hollak
et al, 1997a). Diminished platelet function has also been shown
to improve with imiglucerase therapy (Giona et al, 2006)
although the mechanisms involved are unclear. In vitro
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not directly inﬂuence platelet aggregation function (Gillis et al,
1999).
Malignant haematological disease
A possible association between Gaucher disease and malig-
nancy in older patients was proposed in 1982 following post
mortem studies on 20 deceased type 1 patients revealing
malignant disease in 19 cases. Multiple myeloma was the most
common cancer in both deceased and living patients (Lee,
1982). A subsequent retrospective study involving 48 Israeli
Gaucher patients found a 14Æ7-fold increased risk of develop-
ing a haematopoietic malignancy amongst Gaucher patients
together with an overall 3Æ6-fold risk of developing cancer
compared with healthy controls (Shiran et al, 1993). A later
study, also involving Gaucher patients of Ashkenazi Jewish
origin (n ¼ 505), however, found no excess cancer risk except
for multiple myeloma (Zimran et al, 2005b). Similarly, analysis
of data from 2742 Gaucher patients worldwide enroled in
the ICGG registry also found no overall increased risk of
malignancy but revealed a 5Æ9-fold increased incidence of
multiple myeloma (Rosenbloom et al, 2005). The incidence
of serious co-morbidities and death in ICGG statistics,
however, may be underreported as follow-up data is submitted
voluntarily and no direct information on cancer is requested.
A study of 131 Gaucher patients of mixed ancestry typical of
Gaucher patients in Western Europe, examined both cancer
incidence and mortality compared with Dutch age- and sex-
matched controls. This study, carried out in two centres of
Gaucher disease expertise with consistent patient follow-up for
20 years, found a 2Æ5-fold increased risk of cancer and a 12Æ7-
fold increased risk of haematological cancers. The incidence of
multiple myeloma, in particular, was highly elevated, with
a standardized rate ratio of 51Æ1 (95% conﬁdence interval
6Æ2–184) (de Fost et al, 2006).
Evidence of a higher incidence of multiple myeloma in
Gaucher patients raises questions of whether there are
pathophysiological mechanisms common to both diseases,
and whether the pathophysiology of Gaucher disease
increases the likelihood of developing other haematological
malignancies.
Gaucher disease and multiple myeloma. Several manifestations
of Gaucher disease are common to multiple myeloma, such as
cytopenia, the occurrence of lipid-laden macrophages,
amyloidosis, bone destruction and diffuse osteoporosis
(Costello et al, 2006). As in multiple myeloma, Gaucher
disease is associated with bi- and tri-clonal gammopathies,
monoclonal gammopathy of undetermined signiﬁcance
(MGUS) (Brautbar et al, 2004) and abnormal cytokine
production (Hollak et al, 1997b).
The MGUS is considered a pre-malignant condition in
multiple myeloma and especially when coincident with serum-
free light chains (Rajkumar, 2005). The prevalence of MGUS in
Gaucher disease [ranging from 2Æ2% (Brautbar et al, 2004) to
25% (Pratt et al, 1968)] suggests a possible relationship
between the two diseases. MGUS has been associated with
the evolution of multiple myeloma in Gaucher patients (Brady
et al, 1997) and has been observed together with light chain
proteinuria in a Gaucher patient who developed multiple
myeloma (Harder et al, 2000).
The MGUS incidence in Gaucher patients appears to
increase with age, consistent with the trend in the non-
Gaucher population (Kyle et al, 2006). One study found that
all patients with MGUS were aged 50+ years while patients
without immunoglobulin abnormalities were <50 years (Pratt
et al, 1968). Shoenfeld et al (1982) also noted a direct
correlation between IgA and IgG concentrations and age.
A young age, however, does not preclude immunoglobulin
disorders. In a retrospective study of paediatric type 1 Gaucher
patients, 21 of 23 children (average age: 8Æ5 years) already had
hypergammaglobulinaemia (single or predominantly, multiple
immunoglobulin isotypes) (Wine et al, 2007). IgG, IgA, and
IgM gammopathies were 3Æ2, 4Æ3 and 5Æ1-fold higher, respect-
ively, when compared with adult Gaucher patients (Brautbar
et al, 2004), and seemed to be dependant on disease severity.
Multiple myeloma pathophysiology in the non-Gaucher
population involves genetic abnormalities within the tumour
and interaction between myeloma cells and the bone marrow
microenvironment where the activation of signalling path-
ways stimulates the expansion of the malignant clone
(Bommert et al, 2006). The preferential bone marrow loca-
tion of Gaucher disease and multiple myeloma suggests that
multiple bone marrow alterations induced by Gaucher cells
may create microenvironments that could favour emergence
of a plasma cell clone. In particular, the stimulation of
cytokine release presents a possible shared mechanism of
pathogenesis.
While Gaucher patients are frequently reported to demon-
strate alterations in cytokine/chemokine production that could
be linked to progression of multiple myeloma, there is no
consistent pattern that implicates the involvement of one or
more speciﬁc mediators. For example, IL6, a well-known
stimulus for myeloma cells, has been reported to be elevated
and associated with clonal expansion in Gaucher patients
(Allen et al, 1997). Others have not found elevated IL6, but
report high levels of tumour-necrosis factor a (Michelakakis
et al, 1996), IL1 (Barak et al, 1999) or macrophage colony-
stimulating factor (M-CSF) (Hollak et al, 1997b). CC-chem-
okine ligand 18 (CCL18) is a chemokine thought to be
involved in initiation of an adaptive immune response and
recruitment of naı ¨ve T and B cells toward antigen-presenting
cells and, as such, may contribute to development of antibody-
producing plasma cells. Plasma CCL18 levels have been
reported to be elevated in Gaucher patients, but no deﬁnitive
relationship with monoclonal gammopathies could be identi-
ﬁed (Boot et al, 2004). Similarly, there is currently insufﬁcient
data to associate cytokine production in the bone marrow with
MGUS in Gaucher patients.
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the link between Gaucher disease and haematological
malignancies other than multiple myeloma is less well-
deﬁned, it has been suggested that chronic stimulation of the
immune system by stored glycolipids in Gaucher cells results in
lymphoproliferation (Marti et al, 1988) and may lead to other
B-cell neoplasms such as chronic lymphatic leukaemia and
lymphoma (Shiran et al, 1993) as well as to the proliferation of
myeloid cells. Several reports cite cases of monocytic
leukaemias arising on a background of myelodysplastic
syndrome (Krause et al, 1979; Corbett et al, 1987; Krishnan
et al, 2003; Rosenbloom et al, 2005; de Fost et al, 2006).
Immune system dysfunction resulting from glycolipid storage
may also inﬂuence the development of solid tumours through
reduced immune surveillance due to fewer dendritic cells
(Micheva et al, 2006), reduced NK cell production (Burstein
et al, 1987), compromised T-cell proliferation and IgM
secretion (Pollack et al, 1987) and/or compromised T-cell
function (Bassan et al, 1985).
Discussion
Non-malignant haematological disease
Gaucher disease is associated with well-deﬁned patterns of
cytopenia. In spleen-intact patients, platelets tend to decrease
ﬁrst. With increasing spleen size, haemoglobin levels also
gradually fall, followed lastly by a decline in leucocyte
numbers. In contrast, asplenic patients have normal or even
high platelet counts. If there is severe bone marrow inﬁltration
by Gaucher cells, haemoglobin levels often decline ﬁrst.
Deviations from these patterns may indicate other co-morbi-
dities. For example, a non-splenectomized patient presenting
with a large or slightly enlarged spleen, severe anaemia, but
normal platelet counts is inconsistent with the expected
pattern in Gaucher disease (which would normally include
thrombocytopenia). In this case, it is likely that the anaemia is
not (only) related to Gaucher disease and other causes should
be investigated.
Anaemia. Anaemia is associated with poorer outcomes and
poorer quality of life in a wide variety of disorders including
Gaucher disease. Adoption of recent proposals to increase the
lower limits deﬁning anaemia for adults (Beutler & Waalen,
2006) would enable earlier treatment and elevated treatment
goals for haemoglobin normalization in adult Gaucher
patients. Importantly, the proposals recognize that different
ethnicities may have different requirements – an observation
that may also be extended to different medical conditions
(Boehringer & Darden, 2006) and environments (Ruiz-
Arguelles, 2006). Many Gaucher patients at the severe end of
the disease spectrum present as children (Kaplan et al, 2006).
Should anaemia in children, therefore, also be re-evaluated? In
the absence of revised guidelines, an individualized approach
to Gaucher disease management encourages physicians to
assess, treat and monitor every patient individually for optimal
outcomes (Andersson et al, 2005). This takes into account
variables, such as ethnic origin, age, environment, diet,
co-morbidities and Gaucher disease status in all possible
affected organs and tissues including bone marrow and bone
density, in making disease management decisions.
Serum iron, ferritin and transferrin levels should all be
measured to assess iron status in Gaucher patients. Perls’ stain
on bone marrow aspirate to assess available iron stores should
be performed in all Gaucher patients undergoing bone marrow
aspiration as part of the diagnostic work-up (Rath & Finch,
1948). Levels of serum soluble transferrin receptor are also
valuable in assessing iron status in chronic disease (Nagral
et al, 1999). Serum iron alone is not a useful measurement
parameter as it is too easily affected by diet. Similarly, serum
ferritin alone cannot be used as a marker of iron status in
Gaucher disease as ferritin is often elevated due to chronic
inﬂammation and compromised iron mobilization. Indeed,
ferritin levels can be very high in Gaucher patients, mimicking
those seen in genetic haemachromatosis. However, in Gaucher
disease, iron storage is conﬁned to Gaucher cells and does not
occur in other organs. Treatment of raised ferritin with
phlebotomy (as in genetic haemachromatosis) in a Gaucher
patient is likely, therefore, to exacerbate anaemia.
The percentage of transferrin saturation is the most reliable
measure of iron status in Gaucher disease with c. 16%
saturation considered normal and <10% saturation observed
in established iron deﬁciency. While high ferritin with normal
serum iron and normal transferrin saturation is expected in
Gaucher disease, the possibility of concurrent genetic haem-
achromatosis should be eliminated. Magnetic resonance ima-
ging (MRI) examination of the liver, heart and pancreas using
validated software can be useful in quantitatively assessing iron
burden either if Gaucher disease is suspected or has been
conclusively established. A diagnosis of genetic haemachro-
matosis should be conﬁrmed by genotyping. Routine laborat-
ory criteria may be used to indicate when to screen for
a mutation in HFE (ferritin >500 lg/l, % ferritin saturation
>50%) (Adams, 2006).
Although ferritin levels would be expected to decrease with
enzyme treatment, the response can be slow and cannot be
used to monitor the effects of therapy (Poll et al, 2002). Other
storage parameters, such as chitotriosidase (Hollak et al, 1994)
and/or CCL18/PARC (Boot et al, 2004), provide more sensi-
tive means of monitoring treatment response. Increased
ferritin in an otherwise asymptomatic Gaucher patient is not
sufﬁcient, by itself, for initiating enzyme treatment. The
patient should be assessed completely and monitored closely
for manifestations of Gaucher disease, including MRI assess-
ment of bone marrow inﬁltration.
Recombinant erythropoietin (rEPO) may be used to elevate
red blood cell counts in many conditions, including prior to
surgery. There are no data documenting levels of circulating
plasma EPO in anaemic Gaucher patients and/or how
erythrocyte progenitor cells would respond to erythropoietin.
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effective in Gaucher cell-inﬁltrated bone marrow. EPO has also
been associated with a risk of thrombosis (Lin et al, 2006) and,
in combination with evidence of increased blood cell aggre-
gation in Gaucher disease, may incur unacceptable risks. With
imiglucerase therapy, patients rapidly regain normal haemo-
globin levels and EPO treatment is unnecessary. Only if
patients are refractory to enzyme therapy, perhaps in associ-
ation with other conditions such as myelodysplastic syndrome,
should EPO be considered and then only following measure-
ment of endogenous EPO levels. If endogenous EPO is high,
rEPO treatment will not be effective. The role of EPO, even in
a patient that is not responding to treatment, should be
secondary to further investigations.
Thrombocytopenia and bleeding complications. Thrombocytopenia
may complicate surgical procedures but platelet counts alone
should not be relied upon to assess possible bleeding
complications in Gaucher patients. Even patients who are on
enzyme treatment, and who have normal platelet levels and
normal coagulation factors, may have increased prothrombin
time (PT), activated partial thromboplastin time (aPTT), and/
or abnormal platelet function tests (Hollak et al, 1997a).
As a minimum, PT/aPTT, platelet counts and the PFA-100
 
(Dade Behring, Frankfurt, Germany) test should be carried out
in all Gaucher patients prior to elective surgery to assess
bleeding risk. For those centres without access to the PFA-
100  test, aggregometry and measurement of platelet nucle-
otides may provide alternative assessments. In most Gaucher
patients with platelet counts greater than 100 · 10
9/l, bleeding
time may be a relevant additional parameter. However, this is
an invasive procedure requiring careful standardized assess-
ment and can be unreliable in situations where there are
platelet deﬁciencies. It must also be noted that coagulation
measures can be unreliable in Gaucher patients (Billett et al,
1996) and ﬁbrinogen is likely to be elevated in any inﬂamma-
tory disease.
Surgeons should be especially vigilant of complications in
Gaucher patients with platelets counts of 100 · 10
9/l or below.
DDAVP (desmopressin acetate) is recommended before major
surgery to temporarily increase factor VIII activity (especially
von Willebrand factor) and improve platelet function. Full
assessment of coagulation proﬁle, including correction studies
and assay of coagulation factors, should be performed in every
patient before surgery. Speciﬁc coagulation factor deﬁciencies
should be corrected with recombinant clotting factors (where
available) or factor concentrates. Where PT or APTT are
prolonged and correctable in vitro with normal plasma, but no
speciﬁc factor deﬁciency is identiﬁed, infusion of Octaplas 
(solvent detergent-treated plasma Octapharma Limited, Cov-
entry, UK) or fresh frozen plasma (FFP) is recommended.
Platelet transfusionbeforesurgeryshould becarriedoutin cases
where platelet counts are <50 · 10
9/l, with monitoring during
the operation and repetition if necessary. Where neurological
surgery is to be performed a platelet count threshold of
100 · 10
9/l is recommended (British Committee for Standards
in Haematology, BloodTransfusion TaskForce,2003).Gaucher
patients elected for minor surgery, who have platelet counts of
100 · 10
9/l or below, should be considered for local pre-
treatment with tranexaminic acid or transfusion of Octaplas /
FFP or platelets, depending on the assessment of coagulation
factors, clotting times and platelet function. It is also important
for physicians to consult appropriate national guidelines on the
treatment of asplenic patients, thrombocytopenic patients and
patients with coagulation factor deﬁciencies.
In some non-urgent surgical cases, enzyme therapy may be
used to improve the patient’s haematological proﬁle prior to
surgery (Katz et al, 1999). However, sufﬁcient correction of
platelets may take several months and the appropriateness of
this strategy will depend on each case. A severely affected
asplenic patient would, for example, be expected to respond
rapidly to imiglucerase therapy, and surgery (depending on the
surgical condition) may be postponed for a few months to
reduce bleeding risks.
Thrombocytopenia in Gaucher patients does not preclude
thrombosis. A complete thrombophilic proﬁle should be
performed in patients with recurrent thrombotic episodes.
Additionally, it has been observed that although normal
platelet counts are usually restored within 1 year of starting
enzyme treatment in splenectomized patients, red blood cells
may demonstrate abnormal membrane structure, especially
lipid structure, which makes the cells coagulate and may
predispose thrombotic events. There are reports of pulmonary
hypertension in splenectomized patients (Mistry et al, 2002)
possibly due to reduced deformability of erythrocytes (Bax
et al, 2005), which may be an important mechanism in
pulmonary hypertensive disease. After 1 year of therapy,
platelet function should improve in most patients. If a patient
is refractory to treatment, autoimmune thrombocytopenia
should be considered. Immune thrombocytopenic purpura has
been reported in a Gaucher patient unresponsive to treatment
with corticosteroids (Lester et al, 1984).
Malignant haematological disease
Any physician treating Gaucher patients should be aware of an
increased risk of multiple myeloma and should actively look
for signs of the disease. Current understanding of the
pathophysiologies of multiple myeloma and Gaucher disease
does not, however, allow conclusions to be made about
possible shared disease pathways. While, it is tempting to
speculate that interactions between plasma cells and Gaucher
cells promote the development of clonal expansion in Gaucher
disease, few markers provide early evidence of neoplastic
events in Gaucher patients. There is little data, for example, to
link cytokines important in the development of non-Gaucher
multiple myeloma, such as IL-6, with multiple myeloma in
Gaucher patients. Similarly, although hypergammaglobulinae-
mia is considered a sign of pseudo inﬂammatory syndrome,
which could favour the emergence of monoclonal
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any speciﬁc pattern of hyperimmunoglobulinaemia, including
MGUS, increases the risk of developing multiple myeloma in
Gaucher disease. This is, however, worthy of further investi-
gation in larger patient groups.
As MGUS in the general population carries a risk of
progression to multiple myeloma, it is advisable to check
regularly for monoclonal abnormalities in Gaucher patients. At
baseline, patients (including children) should be examined for
abnormal immunoglobulin proﬁles using a serum protein
electrophoresis and immunoﬁxation test with follow-on
monitoring once every 2 years for patients <50 years of age
and once a year for patients >50 years. It is uncertain whether
criteria such as ‘smouldering myeloma’ and light chain
monitoring (Rajkumar, 2005) are applicable in Gaucher
disease.
Any patient with MGUS should have a bone marrow biopsy
and aspirate examination with karyotyping to detect chromo-
somal abnormalities consistent with multiple myeloma. Rout-
ine follow-up of non-Gaucher patients with MGUS includes
a complete skeletal survey to detect osteolytic lesions. In
Gaucher disease, however, lytic lesions can be part of the
spectrum of Gaucher-related bone abnormalities. Guidelines
for initial assessment of Gaucher patients recommend MRI of
lumbar spine and femora (vom Dahl et al, 2006b). An initial
whole body MRI, if available, may provide background
information in cases where multiple myeloma is suspected or
emerges later in the disease. Only histopathology can make
a deﬁnite diagnosis of multiple myeloma. Microscopic cyto-
logical examination, however, is difﬁcult due to large numbers
of Gaucher cells [especially since multiple myeloma may be
accompanied by pseudo Gaucher cells (Scullin et al, 1979) and
plasma cells may be atypical]. The preferred diagnostic strategy
is immunophenotyping by ﬂow cytometry, a technique
combining CD138/CD38/CD45 staining with CD19 or CD56
staining and screening for malignant plasma cells (Bataille
et al, 2006).
Any growing mass in Gaucher disease detected by imaging,
requires a core biopsy to discriminate tumours and mass-like
inﬁltrations of Gaucher cells (Gaucheromas). An exception is
a mass in the spleen, where biopsy can be hazardous due to
high vascularity and poor accessibility. Alternatives may
include immunophenotyping of peripheral blood, and lymph
node biopsy. A growing mass in the spleen, especially for
patients on imiglucerase therapy, may be one of the rare
indications for splenectomy to exclude lymphoma or another
tumour. Careful measurement of the mass is required, as the
spleen may shrink in response to treatment, making the
Gaucheroma appear proportionately larger and thus mimick-
ing a growing tumour. Gaucheromas are common in the
spleen and liver (Patlas et al, 2002) and are noted in Gaucher-
related skeletal disease (Kaloterakis et al, 2004).
While MGUS in the general population warrants careful
monitoring, no speciﬁc treatment is recommended (Smith et
al, 2006). If B-cell dyscrasia is related to glucocerebroside
storage in Gaucher disease, imiglucerase therapy might be
expected to help resolve immunoglobulin levels. Following
low-dose enzyme therapy signiﬁcant decreases in immuno-
globulin levels have been reported in patients with polyclonal
gammopathies but not with monoclonal gammopathies
(Brautbar et al, 2004). This could indicate that MGUS is not
inherent to Gaucher disease (Zimran et al, 2005a). It is also
possible that clonal expansion of plasma cells has become
uncontrolled. This also raises the question of whether early
treatment could help to prevent Gaucher patients from
developing MGUS and potential B-cell malignancies. Follow-
up of children with Gaucher disease not receiving any speciﬁc
treatment showed that hyperimmunoglobulinopathy (especi-
ally of IgA and IgM) resolved with time in some children.
When enzyme therapy became available to these children,
further normalization occurred during follow-up treatment for
6–7 years. Again greater improvement was noted in IgA and
IgM levels (Wine et al, 2007).
There are no consistent data on the effects of higher enzyme
doses on MGUS and potential B-cell malignancies. If a patient
with MGUS has symptomatic Gaucher disease, Gaucher-
speciﬁc therapy should be used to treat his/her symptoms and
prevent disease progression. In the hypothetical event that
a totally asymptomatic Gaucher patient has MGUS, then
MGUS alone is not an indication to therapy. As well as bone
marrow biopsy for the evaluation of the monoclonal protein,
such a patient should receive a full initial assessment for
Gaucher disease, including MRI, to exclude asymptomatic
bone marrow inﬁltration with Gaucher cells.
Where multiple myeloma is coincident with Gaucher disease,
treatment options require careful consideration. Chemotherapy
normally used to treat multiple myeloma may be too harsh for
Gaucher patients resulting in aggravated cytopenia. Imigluc-
erase before chemotherapy may help improve the patient’s
overall condition and prognosis, but the timeframe is import-
ant. In aggressive myeloma there may be insufﬁcient time for
enzyme therapy to take effect. Currently, there are too few case
reports to determine the best therapeutic options for Gaucher
patients with coincident multiple myeloma or any other
haematological malignancies. There are, for example, no
reports in the literature on stem cell transplantation for the
treatment of haematological malignancies in Gaucher disease.
A diagnosis of multiple myeloma does not, by itself, exclude
a Gaucher patient from receiving Gaucher-speciﬁc treatment.
Each case must be evaluated individually.
Conclusions and recommendations
Gaucher disease is a complex multisystemic disorder that
does not exclude other acute or chronic conditions. How-
ever, the precise relationship between Gaucher disease and
certain comorbidities, especially cancer, remains unclear.
There is insufﬁcient information to conclude that multiple
myeloma, or other cancers, represent disease progression
per se in Gaucher patients, although it is hypothesized that
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may be involved in the multistep aetiology of malignancy.
The use of plasma MGUS, immunoglobulin light chains, or
cytokines for monitoring the pathogenesis of Gaucher-related
malignancies currently remains speculative. Further sharing
of information through the ICGG registry, or other
specialized databases, may help clarify their role in the
future, and may provide additional therapeutic goals for
Gaucher disease. Until then, clinicians can only remain
vigilant to co-morbidities in Gaucher disease, and learn from
the non-Gaucher community in recognizing possible early
indicators of co-existent disease. The panellists made several
recommendations for the treatment and monitoring of
Gaucher patients, and for increasing awareness of poss-
ible signs of haematological co-morbidity (summarized in
Table III).
Table III. Recommendations for the management of the haematological aspects of Gaucher disease.
Grade *
General haematology
Gaucher disease does not exclude other conditions. Physicians should be vigilant to co-existent conditions that may require speciﬁc
treatments
B and C
The increased lower limits of haemoglobin deﬁning anaemia [Beutler & Waalen, 2006] should be employed in Gaucher disease
assessment and treatment monitoring
B and C
Awareness of expected patterns of cytopenia in Gaucher disease should be increased to alert physicians of co-morbidities e.g. normal
haemoglobin and low platelets counts are outside the norm for asplenic Gaucher patients. Further investigations are required
C
At baseline, thorough red blood cell studies should be performed (haemoglobin, red cell indices, reticulocyte count, blood ﬁlm
studies)
C
At baseline A complete iron metabolism evaluation should be carried out (serum iron, transferrin saturation, ferritin, and B12
status)
C
Appropriate existing guidelines should be followed for co-existent co-morbidities (e.g. asplenic state, coagulapathy, iron or vitamin
B12 deﬁciency)
C
If ferritin and transferrin saturation are increased, look for possible concurrent genetic haemachromatosis using MRI and HFE
testing even if Gaucher disease is frankly suspected/established
C
Normal transferrin saturation, normal serum iron, and high levels of ferritin are expected in Gaucher disease. Do not phlebotomize C
Be suspicious of ferritin that is normal or just above normal – especially in patients with bone disease or taking non-steroidal anti-
inﬂammatory drugs
C
Some Gaucher patients (especially women and children) could be iron deﬁciency anaemic. If serum iron and transferrin saturation
are low with normal or slightly elevated ferritin, the patient may need treatment for iron deﬁciency anaemia
B
Surgeons should be made aware of the possible risks of bleeding complications involved in surgery in Gaucher patients even with
platelet counts >50–100 · 10
9/l
C
Bleeding risk assessment: aPPT, PT, platelet counts, and PFA-100  test should all be carried out. Bleeding time may be unreliable B and C
Prevention of bleeding: DDAVP, coagulation factor, plasma or platelet transfusions may be necessary in cases scheduled for major
surgery where platelets counts are <100 · 10
9/l with abnormal APTT, PT or PFA 100, or in cases with platelets <50 · 10
9/l
B and C
Haematological malignancy
Haematologists should recognize the higher incidence of multiple myeloma in Gaucher disease and, possibly, other
myeloproliferative/lymphoproliferative malignancies
B
Assessment of abnormal mass detected on imaging: a core biopsy and histological assessment should be carried out with the possible
exception of masses in the spleen, which can be hazardous to biopsy in Gaucher patients
C
Cytokine levels are not considered predictive of any increased risk of malignancy and should only be carried out in a research setting
and not for clinical monitoring
B and C
Adults and paediatric patients should have an immunoglobulin proﬁle (plus clonality) determined at diagnosis with monitoring
every 2 years for patients <50 years and once a year for those 50+ years
C
If MGUS is found, a bone marrow biopsy and aspirate should be carried out with full cytogenetic proﬁle B
For patients with MGUS, general MGUS guidelines should be followed including the (potential) use of light chain assays C
The coincidence of Gaucher disease and multiple myeloma, by itself, does not exclude the patient from receiving imiglucerase C
Future studies
Future studies should focus on the utility of early treatment to prevent immunoglobulin abnormalities and multiple myeloma
Reports of all cases of haematological cancer in Gaucher disease should be pooled so that the outcomes of chemotherapy and other
treatments can be assessed to determine best practice in treating patients with malignancies
On-going studies into the pathophysiology of Gaucher disease are essential in identifying the mechanisms involved in cancer and
other co-morbidities
*Smith et al, 2006: Grade B (Evidence level IIa, IIb and III) Recommendation based on well-conducted studies but no randomized controlled trials on
the topic of recommendation; Grade C (Evidence level IV) Evidence from expert committee reports and/or clinical experiences of respected
authorities.
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